US Patent Litigations are now available. Check here

IP Verse

Tablet Formulation Comprising A Peptide And A Delivery Agent

PatentPatent Analysis

EP2863895

NOVO NORDISK
Application Number
EP13729743A
Filing Date
Jun 19, 2013
Status
Revoked
Oct 21, 2022
Grant Date
Apr 14, 2021
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP3300721B2
EP2729202B2
EP4054620B1

Biblio Summary

The patent EP2863895B1 was granted on Apr 14, 2021 by Novo Nordisk The patent is currently Revoked.

Patents Cited during Opposition New

Patent citations in opposition refer to prior patents or publications that may challenge the validity of a contested patent. These references help assess whether the invention is truly novel or overlaps with existing intellectual property.

Citation PhasePatent NumberPatent LinkCited Text
OppositionWO2010020978
 N/A
OppositionWO2006097537
 N/A
OppositionWO2012080471
 N/A
OppositionJP4585037B
 N/A
OppositionWO2007121318
 N/A
OppositionUS2009124639
 N/A
OppositionWO2013139695
 N/A
OppositionWO2013139694
 N/A
OppositionWO2013189988
 N/A
OppositionWO2008109385
 N/A
OppositionUS2011142800
 N/A
OppositionWO2004104018
 N/A
OppositionWO2007011958
 N/A

Dossier Documents of the Patent

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents